- Home
- TBI vs CRGX Comparison
TBI vs CRGX Comparison
Compare TBI & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- CRGX
- Stock Information
- Founded
- TBI 1985
- CRGX 2021
- Country
- TBI United States
- CRGX United States
- Employees
- TBI 4200
- CRGX N/A
- Industry
- TBI Professional Services
- CRGX
- Sector
- TBI Consumer Discretionary
- CRGX
- Exchange
- TBI Nasdaq
- CRGX Nasdaq
- Market Cap
- TBI 204.9M
- CRGX 190.0M
- IPO Year
- TBI 1996
- CRGX 2023
- Fundamental
- Price
- TBI $6.64
- CRGX $4.16
- Analyst Decision
- TBI Buy
- CRGX Hold
- Analyst Count
- TBI 1
- CRGX 7
- Target Price
- TBI $10.00
- CRGX $4.67
- AVG Volume (30 Days)
- TBI 229.7K
- CRGX 586.4K
- Earning Date
- TBI 08-04-2025
- CRGX 08-11-2025
- Dividend Yield
- TBI N/A
- CRGX N/A
- EPS Growth
- TBI N/A
- CRGX N/A
- EPS
- TBI N/A
- CRGX N/A
- Revenue
- TBI $1,534,794,000.00
- CRGX N/A
- Revenue This Year
- TBI $0.80
- CRGX $57.81
- Revenue Next Year
- TBI $6.90
- CRGX N/A
- P/E Ratio
- TBI N/A
- CRGX N/A
- Revenue Growth
- TBI N/A
- CRGX N/A
- 52 Week Low
- TBI $3.45
- CRGX $3.00
- 52 Week High
- TBI $12.29
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- TBI 56.19
- CRGX 45.07
- Support Level
- TBI $6.27
- CRGX $4.33
- Resistance Level
- TBI $7.05
- CRGX $4.36
- Average True Range (ATR)
- TBI 0.38
- CRGX 0.19
- MACD
- TBI -0.06
- CRGX -0.04
- Stochastic Oscillator
- TBI 37.40
- CRGX 21.76
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.